tocainide

Trade name: tonocard

Small moleculeapproved

Approved

Nov 9, 1984

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose-dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide. The recommended initial dosage is 400 mg every 8 hours. The usual adult dosage is between 1200 and 1800 mg/day in a three-dose daily divided regimen. Doses beyond 2400 mg per day have been administered infrequently. Patients who tolerate the t.i.d. the regimen may be tried on a twice-daily regimen with careful monitoring. Tocainide commonly produces minor, transient, nervous system and gastrointestinal adverse reactions, but is otherwise generally well tolerated. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1980s

  1. Nov 9, 1984

    AstraZeneca — Earliest FDA Approval

  2. Nov 9, 1984

    Astra — NDA Secondary Org

  3. Nov 9, 1984

    AstraZeneca — NDA Secondary Org

  4. Nov 9, 1984

    AstraZeneca — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewNov 9, 1984

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cccc(C)c1NC(=O)C(C)N
Mol. weight
192.26 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • 2-amino-2',6'-propionoxylidide
  • 2-amino-2',6'-propionoxylidide
  • 2-amino-n-(2,6-dimethylphenyl)propanamide
  • 2-amino-n-(2,6-dimethylphenyl)propanamide
  • 2-amino-n-(2,6-dimethylphenyl)propionamid
  • 2-amino-n-(2,6-dimethylphenyl)propionamid
  • alanyl-2,6-xylidide
  • alanyl-2,6-xylidide
  • dl-tocainide
  • (rs)-tocainide
  • tocainida
  • tocainida
  • tocainide
  • tocainide
  • tocainide
  • tocainide
  • tocainide
  • tocainide
  • tocainide
  • tocainide
  • (+/-)-tocainide
  • tocainide hcl
  • tocainide hcl
  • tocainide hcl
  • tocainide hydrochloride
  • tocainide hydrochloride
  • tocainide hydrochloride
  • tocainide hydrochloride
  • tocainide hydrochloride
  • tocainide hydrochloride
  • tocainide hydrochloride
  • tocainidum
  • tocainidum
  • tonocard
  • tonocard
  • tonocard
  • w-36095
  • w-36095
  • xylotocan
  • xylotocan

Organizations

Marketing (3)

OrganizationOrg typeRelationshipDate
AstraFor profitNDA2Nov 9, 1984
AstraZenecaFor profitNDA2Nov 9, 1984
AstraZenecaFor profitNDANov 9, 1984